Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
1999-03-12
2001-07-03
Killos, Paul J. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S517000, C514S518000, C514S645000, C562S030000, C562S066000, C564S253000, C564S282000, C564S284000
Reexamination Certificate
active
06255353
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to compounds, compositions and methods for inhibiting (preventing and treating) neovascularization (angiogenesis).
2. Prior Work
Malignant neovascularization (angiogenesis), particularly ocular neovascularization associated with macular degeneration, diabetic retinopathy and retinopathy of prematurity, as well as psoriasis, rheumatoid arthritis and solid tumors, is a serious medical condition.
The most common cause of blindness in Americans over age 55 is age-related macular degeneration (AMD); for those under 40, diabetes is the most common cause of blindness. Neovascularization is the root cause of blindness in both cases. Neovascularization is the result of a compromise of the vascular bed supplying the retina, and may be regarded as a response to tissue ischemia (or hypoxia). Clinicians have long recognized the high probability of neovascularization in individuals who have lost part of the capillary bed due to diabetes, or who have experienced occlusion of a branch vein of the retina.
The primary current treatment for neovascularization is destructive. Photocoagulation is used to reduce the volume of hypoxic tissue in diabetic retinopathy or to destroy vessels in AMD. Cryotherapy may be used to destroy hypoxic retina in infants. There is an urgent need for therapeutic intervention in these disease processes. No known therapeutic treatment can prevent neovascularization following loss of capillaries in diabetes, reduce the risk of further neovascularization in wet AMD, or offer reassurance to patients at risk because of heredity, diabetes, or age.
Any progress toward therapeutic management and prevention of neovascularization will greatly reduce the social and economic impact of diabetes and AMD.
One of the limitations of the newer therapeutic approaches to neovascularization that are under development, particularly those involving growth factors, is that they may also inhibit wound repair or the development of collateral vessels in mild occlusion of coronary arteries.
STATEMENT OF THE INVENTION
It has now been found that certain simple chemical agents, referred to herein as nitrone-related therapeutics or “NRTs”, when administered to a patient susceptible to angiogenesis, can intervene and inhibit its progress.
In one aspect this invention provides a method for inhibiting angiogenesis in a patient susceptible thereto by administering to that patient an effective angiogenesis-inhibiting dose of one or more NRTs.
In a second aspect, this invention provides pharmaceutical compositions for use in such methods of treating. These compositions include one or more NRTs in a pharmaceutically acceptable carrier.
In a third aspect, this invention provides NRTs useful in these compositions and therapeutic methods.
DETAILED DESCRIPTION OF THE INVENTION
REFERENCES:
patent: WO 95/17876 (1995-07-01), None
patent: WO 97/39751 (1997-10-01), None
Narducy Kenneth W.
Waterbury Lowell D.
Wilcox Allan L.
Burns Doane , Swecker, Mathis LLP
Centaur Pharmaceuticals, Inc.
Killos Paul J.
LandOfFree
Inhibition of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2452418